Investor Education Series: Angel Investing: Why Biotech?
An introduction to the role of angel investors in early-stage bioscience companies and a look at successful investment pathways in the sector.
An introduction to the role of angel investors in early-stage bioscience companies and a look at successful investment pathways in the sector.
A high-level exploration of biotech subfields and how different innovations—from biologics to digital tools—reach commercialization.
Guidance on how to evaluate biotech teams, technologies, and financial structures when considering early-stage investment.
An overview of regulatory frameworks that impact biotech startups and how these shape investment timelines and risks.
Discussion of common risk factors in biotech investing, exit scenarios, and strategies to balance exposure across a diversified portfolio, including Angel Tax Credits.
An investor-focused session featuring a select group of regional founders presenting science-based ventures seeking capital and strategic support.
We’re inviting a small group of new and seasoned investors to take part in a workshop designed to make life sciences investing in Kansas City clearer, easier, and more rewarding....
A recurring, peer-to-peer gathering for investors and capital partners to have thoughtful conversations about markets, portfolio strategy, emerging sectors, and capital deployment.
Historical and conceptual grounding in bioscience as an investable asset class and the role of angel investors in translating research into real-world solutions.
A recurring, peer-to-peer gathering for investors and capital partners to have thoughtful conversations about markets, portfolio strategy, emerging sectors, and capital deployment.
Overview of major life sciences subsectors—including agtech, medical biotech, biotools, bioindustrials, and digital health—with emphasis on market potential and risk profiles.
A structured framework for evaluating scientific validity, IP strength, regulatory feasibility, management quality, and financial readiness.